Lantheus Holdings, Inc. (LNTH)
USD 89.5
(-1.56%)
USD 89.5
(-1.56%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 616.12 Million USD | 10.47% |
| 2022 | 557.71 Million USD | 241.9% |
| 2021 | 163.12 Million USD | -17.49% |
| 2020 | 197.69 Million USD | 7.49% |
| 2019 | 183.92 Million USD | -30.25% |
| 2018 | 263.7 Million USD | -0.63% |
| 2017 | 265.39 Million USD | -3.3% |
| 2016 | 274.46 Million USD | -21.55% |
| 2015 | 349.85 Million USD | -12.38% |
| 2014 | 399.28 Million USD | 0.06% |
| 2013 | 399.03 Million USD | 0.05% |
| 2012 | 398.82 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 562.46 Million USD | 0.05% |
| 2024 Q2 | 562.82 Million USD | 0.22% |
| 2023 FY | 616.12 Million USD | 10.47% |
| 2023 Q3 | 614.99 Million USD | 4.15% |
| 2023 Q4 | 616.12 Million USD | 0.18% |
| 2023 Q1 | 558.53 Million USD | 0.15% |
| 2023 Q2 | 590.48 Million USD | 5.72% |
| 2022 Q4 | 557.71 Million USD | 233.14% |
| 2022 Q2 | 171.44 Million USD | 7.58% |
| 2022 Q1 | 159.36 Million USD | -2.3% |
| 2022 FY | 557.71 Million USD | 241.9% |
| 2022 Q3 | 167.41 Million USD | -2.35% |
| 2021 FY | 163.12 Million USD | -17.49% |
| 2021 Q1 | 171.47 Million USD | -13.27% |
| 2021 Q2 | 169.24 Million USD | -1.3% |
| 2021 Q3 | 166.74 Million USD | -1.48% |
| 2021 Q4 | 163.12 Million USD | -2.17% |
| 2020 FY | 197.69 Million USD | 7.49% |
| 2020 Q1 | 181.48 Million USD | -1.33% |
| 2020 Q3 | 204.66 Million USD | -2.54% |
| 2020 Q4 | 197.69 Million USD | -3.41% |
| 2020 Q2 | 210.01 Million USD | 15.72% |
| 2019 Q2 | 188.7 Million USD | -28.33% |
| 2019 Q4 | 183.92 Million USD | -1.31% |
| 2019 FY | 183.92 Million USD | -30.25% |
| 2019 Q1 | 263.29 Million USD | -0.16% |
| 2019 Q3 | 186.37 Million USD | -1.24% |
| 2018 Q4 | 263.7 Million USD | -0.16% |
| 2018 Q1 | 264.97 Million USD | -0.16% |
| 2018 FY | 263.7 Million USD | -0.63% |
| 2018 Q2 | 264.55 Million USD | -0.16% |
| 2018 Q3 | 264.13 Million USD | -0.16% |
| 2017 Q4 | 265.39 Million USD | -0.05% |
| 2017 FY | 265.39 Million USD | -3.3% |
| 2017 Q3 | 265.52 Million USD | -0.15% |
| 2017 Q2 | 265.92 Million USD | -0.15% |
| 2017 Q1 | 266.33 Million USD | -2.96% |
| 2016 Q4 | 274.46 Million USD | -6.83% |
| 2016 FY | 274.46 Million USD | -21.55% |
| 2016 Q1 | 349.34 Million USD | -0.15% |
| 2016 Q2 | 348.83 Million USD | -0.15% |
| 2016 Q3 | 294.58 Million USD | -15.55% |
| 2015 Q3 | 350.36 Million USD | -0.16% |
| 2015 Q4 | 349.85 Million USD | -0.15% |
| 2015 Q2 | 350.92 Million USD | -12.13% |
| 2015 Q1 | 399.34 Million USD | 0.02% |
| 2015 FY | 349.85 Million USD | -12.38% |
| 2014 Q4 | 399.28 Million USD | 0.02% |
| 2014 FY | 399.28 Million USD | 0.06% |
| 2014 Q1 | 399.09 Million USD | 0.02% |
| 2014 Q2 | 399.15 Million USD | 0.02% |
| 2014 Q3 | 399.22 Million USD | 0.02% |
| 2013 FY | 399.03 Million USD | 0.05% |
| 2013 Q1 | 398.87 Million USD | 0.01% |
| 2013 Q3 | 398.98 Million USD | 0.01% |
| 2013 Q2 | 398.92 Million USD | 0.01% |
| 2013 Q4 | 399.03 Million USD | 0.01% |
| 2012 Q4 | 398.82 Million USD | 0.0% |
| 2012 FY | 398.82 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | -20198.312% |
| Safety Shot Inc | 304.9 Thousand USD | -201969.156% |
| Bright Green Corporation | 201.78 Thousand USD | -305239.399% |
| Embecta Corp. | 1.62 Billion USD | 62.094% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -98.962% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -576.493% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | -25.749% |
| Dynavax Technologies Corporation | 252.41 Million USD | -144.088% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -22.845% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -4523.465% |
| Pacira BioSciences, Inc. | 513.79 Million USD | -19.916% |
| PainReform Ltd. | 30 Thousand USD | -2053643.333% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -114201.112% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -114201.112% |
| SCYNEXIS, Inc. | 12.15 Million USD | -4967.218% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -525920.883% |
| Journey Medical Corporation | 14.62 Million USD | -4113.671% |
| Alpha Teknova, Inc. | 13.25 Million USD | -4549.634% |
| Procaps Group, S.A. | 28.41 Million USD | -2068.684% |
| Theratechnologies Inc. | 51.26 Million USD | -1101.933% |
| Harrow Health, Inc. | 183.17 Million USD | -236.363% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -708087.356% |
| Biofrontera Inc. | 804 Thousand USD | -76532.214% |
| DURECT Corporation | 2.7 Million USD | -22702.48% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1756.016% |
| Cronos Group Inc. | 1.55 Million USD | -39420.398% |
| OptiNose, Inc. | 611 Thousand USD | -100738.462% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | -23.643% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1702.056% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -135311.648% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -914.278% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -4719.431% |
| Radius Health, Inc. | 339.66 Million USD | -81.391% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -5906.268% |
| Phibro Animal Health Corporation | 458.28 Million USD | -34.44% |
| Procaps Group S.A. | 28.41 Million USD | -2068.684% |
| Alvotech | 1.02 Billion USD | 40.052% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -9332.379% |
| Viatris Inc. | 16.18 Billion USD | 96.194% |
| Rockwell Medical, Inc. | 8.29 Million USD | -7329.435% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -5564.457% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -183274.852% |
| Tilray Brands, Inc. | 287.93 Million USD | -113.98% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -411.263% |
| Shineco, Inc. | 10.01 Million USD | -6050.57% |
| PetIQ, Inc. | 437.82 Million USD | -40.725% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -293291.905% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -138.53% |
| Alimera Sciences, Inc. | 64.48 Million USD | -855.392% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -1499.738% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -455986.728% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -8884.837% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -85472.639% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2740173.083% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1780.717% |
| Hempacco Co., Inc. | 5.93 Million USD | -10288.179% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 40.052% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -995.992% |
| Currenc Group, Inc. | 2.5 Million USD | -24476.362% |
| Kamada Ltd. | 7.43 Million USD | -8183.45% |
| Indivior PLC | 235.66 Million USD | -161.438% |
| Evoke Pharma, Inc. | 5 Million USD | -12222.46% |
| Flora Growth Corp. | 942 Thousand USD | -65305.839% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2740173.083% |
| Evolus, Inc. | 120.35 Million USD | -411.904% |
| HUTCHMED (China) Limited | 48.18 Million USD | -1178.555% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | -4.57% |
| Akanda Corp. | 2.49 Million USD | -24572.998% |